Work

CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps7062

Authors: Farhad Ravandi, Stephen Anthony Strickland, Scott R. Solomon, Aziz Nazha, Roland B. Walter, Ilaria Valimberti, Alessia Tagliavini, Caterina Fiesoli, Monica Binaschi, Krzysztof Brzozka, Simone Baldini, Steffen Heeger, Andrea Ugo Pellacani

Institutions: The University of Texas MD Anderson Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Northside Hospital, Cleveland Clinic, Fred Hutch Cancer Center, Menarini Group (Italy), Selvita (Poland)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954088728

Cites:

Cited by:

Related to: 10